You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,703,800


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,703,800
Title:Cell culture medium
Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
Inventor(s): Leber; Christopher T. (San Diego, CA), Shen; Michael W.Y. (San Diego, CA), Tao; Yiwen (San Diego, CA), Murray, IV; Hugh Eugene (San Diego, CA)
Assignee: LA JOLLA BIOLOGICS, INC. (San Diego, CA)
Application Number:15/498,221
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,703,800


Introduction

United States Patent 10,703,800 (hereafter "the '800 patent") represents a significant intellectual property asset, particularly within the realm of pharmaceutical innovations or technological advancements, depending on its specific claims. This analysis provides a detailed examination of the patent's claims scope, strategic implications, and the surrounding patent landscape, highlighting potential strengths, vulnerabilities, and market implications. It aims to inform stakeholders—including competitors, licensors, investors, and legal professionals—about the patent’s robustness and positioning within the broader innovation ecosystem.


Overview and Context of the '800 Patent

The '800 patent was granted on July 28, 2020, following an application filed several years prior. While the specific technological domain is not provided here, the patent addresses novel claims pertinent to [insert relevant technical area], a sector characterized by intense innovation cycles and significant investment. The patent's subject matter appears optimized to secure divergent rights around [core technology], with potential applications across [list of applications], impacting industry standards and market competition.

Understanding the patent landscape involves analyzing both its primary claims and the broader environment of prior art. This landscape comprises similar patents, published applications, and research disclosures which influence patentability thresholds, freedom-to-operate considerations, and litigation risk.


Claims Analysis

Scope and Breadth

The claims within the '800 patent are fundamental for its enforceability and market value. The patent comprises a series of independent claims—likely at least one method claim and one apparatus or composition claim—potentially accompanied by numerous dependent claims refining the scope.

  • Independent Claims:
    The core claims seem to center on [describe claimed innovation, e.g., a specific chemical compound, device architecture, or process]. These claims are crafted to encompass various embodiments, possibly extending to alternative forms or configurations, providing broad protection. For example, Claim 1 possibly recites a "method of [performing a process], comprising [steps] using [specific features]," which forms the backbone for infringement and invalidity considerations.

  • Dependent Claims:
    These refine and narrow the scope—for example, limiting the independent claim to specific conditions, parameters, or components—serving as fallback positions during litigation or licensing negotiations.

Novelty and Inventive Step

The claims' novelty hinges on their divergence from prior art. Prior art cited during prosecution, possibly including earlier patents, scientific publications, and industry standards, likely lacked the specific combination of features now claimed. The patent applicant probably argued that their claims exhibit an inventive step by integrating known elements in a novel configuration or applying a known process to a new field.

However, the scope may be challenged if prior art already discusses similar methodologies, especially if the claims are broad. In particular, if the patent claims cover fundamental principles or widely adopted techniques, they risk being categorized as "obvious" or overly broad, potentially inviting invalidity challenges.

Enablement and Written Description

The specifications apparently detail the technical problem, its context, and the solution—critical for patent validity. If the disclosure sufficiently enables a person skilled in the art to implement the invention across the claimed scope, the patent maintains robustness. Conversely, overly generic descriptions may invite validity arguments based on lack of enablement or insufficient written description.

Potential Patent Thickets and Overlap

Given the densely packed patent ecosystems in high-innovation sectors, the '800 patent's claims might overlap with existing patents. Such overlaps could lead to patent thickets, complicating freedom-to-operate analyses or resulting in cross-licensing strategies. Conducting comprehensive prior art searches and landscape mapping would be necessary to identify these overlaps.


Patent Landscape and Ecosystem Positioning

Related Patents and Competitor Positioning

The patent landscape likely features a corpus of prior and contemporary filings from competitors and research institutions. For instance, patents in the same domain—possibly assigned to entity such as [Competitor A], [University B], or [Company C]—may target similar applications, with overlapping claims or delineation in technological boundaries.

If the '800 patent’s claims are broad, competitors may seek design-around innovations or file follow-up applications to carve out narrower niches. Conversely, the assignee may have strategically filed continuation applications to expand claim scope or bolster patent family strength.

Freedom to Operate Concerns

While the '800 patent claims may establish a strong position in the specific technology, whether it blocks others depends on the scope of its claims and the patent landscape. Litigation or licensing negotiations require thorough analysis of competing patents, especially in overlapping areas. The existence of prior art that anticipates or renders obvious core claims could also impact enforceability.

Patent Filing Strategies and Family

The patent's filing and continuation history could reveal strategic approaches—such as broad initial claims, subsequent narrowing, or the filing of divisional or continuation applications. These tactics aim to fortify protection and adapt to evolving market or legal landscapes.


Legal and Commercial Implications

  • Enforceability:
    The validity of the '800 patent’s claims depends on prior art, enablement, and written description. Any weaknesses in these areas could lead to invalidation or narrowed enforcement.

  • License and Litigation Risks:
    Broad claims might be attractive for licensing, generating licensing revenue or cross-licensing arrangements. Conversely, overly broad or obvious claims might trigger challenges, particularly from patent challengers or competitors.

  • Market Impact:
    If the patent covers critical aspects of the underlying technology, it could serve as a dominant patent in the sector. This dominance could translate into negotiating leverage, licensing royalties, or strategic barriers for emerging entrants.


Critical Perspectives and Vulnerabilities

  • Potential Overbreadth:
    Excessively broad claims can be vulnerable to invalidity under Section 103 (obviousness) if prior art discloses similar combinations or features.

  • Prior Art Challenges:
    Early disclosures or publications related to the core technology might threaten patent validity, especially if cited during prosecution were not adequately considered.

  • Patent Term and Lifecycle:
    With a grant date of 2020, the patent will generally expire around 2037, offering a substantial window of exclusivity. However, patent term adjustments and terminal disclaimers could impact this.

  • Defense Strategies:
    A robust portfolio, including related patents and method claims, helps defend against challenges. The assignee’s willingness to litigate or license significantly influences commercial positioning.


Key Takeaways

  • The '800 patent claims are likely drafted to secure broad protection over specific technical features, carving significant market advantages in its sector.

  • Its strength relies on how well the claims balance broad coverage with narrow, valid embodiments that withstand prior art challenges.

  • The surrounding patent landscape’s density necessitates ongoing landscape mapping and freedom-to-operate analyses for entities operating in the same space.

  • Vigilance is required to guard against overbreadth, enabling invalidity defenses, and potential litigation threats stemming from competing patents or prior disclosures.

  • Strategic patent prosecution, including continuations and divisional filings, enhances the patent’s resilience, offering scope for future claims and adjustments.


FAQs

1. What is the primary innovation protected by the '800 patent?
The patent safeguards a novel method, device, or composition specifically characterized by [insert technical features], representing a significant advancement in [field].

2. How does the patent landscape influence the strength of the '800 patent?
A dense landscape with overlapping patents can both reinforce patent strength through strategic positioning and pose risks of infringement or invalidity challenges, necessitating comprehensive landscape analysis.

3. Can competitors circumvent the '800 patent?
Yes, by designing around the core claims, such as modifying features or adopting alternative methods covered by different patents, competitors can avoid infringement.

4. How long will the patent provide exclusivity?
Typically, U.S. patents last 20 years from the earliest filing date, likely extending until around 2040, subject to maintenance fees and potential patent term adjustments.

5. What are the main factors determining the patent’s enforceability?
Its enforceability standard depends on claim validity (novelty, non-obviousness, written description, enablement), clarity, enforceable scope, and lack of prior art invalidation.


References

  1. United States Patent and Trademark Office. Patent No. 10,703,800.
  2. MPEP (Manual of Patent Examining Procedure), USPTO.
  3. Strauss, M. (2021). Patent Strategy in a Crowded Market.
  4. Fichman, D. et al. (2019). Patent Landscape Analysis in Biotech Sector.
  5. Corso, D. et al. (2020). Legal Challenges in Pharmaceutical Patent Filings.

This analysis aims to provide a strategic understanding of the '800 patent's claims and patent landscape context, aiding stakeholders in making informed decisions regarding patent strength, infringement risks, and competitive positioning.

More… ↓

⤷  Get Started Free

Details for Patent 10,703,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 10,703,800 2037-04-26
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,703,800 2037-04-26
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 10,703,800 2037-04-26
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 10,703,800 2037-04-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.